| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 45 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human DDI2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DDI2抗体的虚构参考文献示例(仅供示例用途，非真实文献)：
---
1. **文献名称**: *Development of a High-Specificity Monoclonal Antibody for Human DDI2 Protein Detection*
**作者**: Zhang L., et al.
**摘要**: 本研究报道了一种新型单克隆抗体的开发，该抗体针对人源DDI2蛋白的C端结构域，验证了其在Western blot和免疫荧光中的高特异性，并证实DDI2在DNA损伤修复通路中的表达上调。
2. **文献名称**: *DDI2 Expression Correlates with Chemotherapy Resistance in Ovarian Cancer*
**作者**: Tanaka K., et al.
**摘要**: 通过免疫组化分析，发现DDI2在卵巢癌组织中的高表达与铂类化疗耐药性显著相关，提示其作为预后标志物的潜在价值，并利用抗DDI2抗体验证了蛋白定位。
3. **文献名称**: *Structural Insights into DDI2-Proteasome Interaction via Cryo-EM*
**作者**: Müller R., et al.
**摘要**: 采用冷冻电镜技术解析了DDI2与蛋白酶体复合物的结合机制，通过特异性抗体标记揭示了DDI2在蛋白质质量控制中的调控作用。
4. **文献名称**: *DDI2 Knockdown Impairs Viral Clearance in Macrophages*
**作者**: Chen H., et al.
**摘要**: 研究利用抗DDI2抗体进行功能抑制实验，证明DDI2通过调控NF-κB通路影响巨噬细胞对RNA病毒的清除能力，为抗病毒治疗提供新靶点。
---
注：以上文献信息为虚构，实际引用需查询真实数据库(如PubMed)。
The DDI2 (DNA-damage inducible protein 1 homolog 2) antibody is a research tool targeting the DDI2 protein, a key regulator in cellular stress response pathways. DDI2. a member of the aspartic protease family, plays a critical role in activating the transcription factor Nrf1 (NFE2L1) under proteasome dysfunction. When proteasome activity is impaired, DDI2 cleaves Nrf1 from the endoplasmic reticulum membrane, enabling its translocation to the nucleus to initiate the transcription of proteasome subunit genes, thereby restoring proteostasis. This DDI2-Nrf1 axis is vital for maintaining cellular adaptation to oxidative stress, protein aggregation, and proteotoxic conditions.
DDI2 antibodies are widely used in studies investigating protein quality control mechanisms, neurodegenerative diseases (e.g., Alzheimer’s, Parkinson’s), and cancer, where proteasome inhibition therapies (e.g., bortezomib) are employed. Researchers utilize these antibodies in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect DDI2 expression levels, subcellular localization, and its interaction with Nrf1. Recent studies also explore DDI2’s potential role in drug resistance, as cancer cells may exploit the DDI2-Nrf1 pathway to counteract proteasome inhibitor treatments. Commercial DDI2 antibodies are typically validated for specificity in human, mouse, or rat models, aiding mechanistic insights into proteasome regulation and stress adaptation.
×
